[EN] PROCESS FOR PREPARATION OF LANREOTIDE ACETATE<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ACÉTATE DE LANRÉOTIDE
申请人:EMCURE PHARMACEUTICALS LTD
公开号:WO2019077507A1
公开(公告)日:2019-04-25
The invention relates to an improved method for the solution phase synthesis of Lanreotide acetate (1) comprising coupling of two suitably protected tetrapeptide fragments wherein the threonine hydroxyl is protected, to give an octapeptide, which on deprotection, oxidation, followed by treatment with acetic acid provides Lanreotide acetate (1) having desired purity.
Compounds having the formula
1
are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.
Compounds with growth hormone releasing properties
申请人:Novo Nordisk A/S
公开号:US05977178A1
公开(公告)日:1999-11-02
Compounds of peptide mimetic nature having the general formula I ##STR1## wherein a and b are independently 1 or 2, R.sup.1 and R.sup.2 are independently H or C.sub.1-6 alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.
NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF
申请人:Boyd A. Vincent
公开号:US20070021434A1
公开(公告)日:2007-01-25
The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides methods for identifying amide-based, non-nucleoside compounds having antiviral activity.
COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE
申请人:Cameron Dale Russell
公开号:US20080171783A1
公开(公告)日:2008-07-17
The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha and polymerase gamma.